A new phase III study shows superior efficacy of fludarabine plus alemtuzumab combination therapy over fludarabine alone in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL). However, the study has limitations and the findings can not be generalized to the majority of patients with CLL.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Keating, M. J. et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 99, 3554–3561 (2002).
Stilgenbauer, S. et al. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J. Clin. Oncol. 27, 3994–4001 (2009).
Lozanski, G. et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 103, 3278–3281 (2004).
Hillmen, P. et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J. Clin. Oncol. 25, 5616–5623 (2007).
Jaglowski, S. M., Alinari, L., Lapalombella, R., Muthusamy, N. & Byrd, J. C. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. Blood 116, 3705–3714.
Elter, T. et al. Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial. Lancet Oncol. http://dx.doi.org/10.1016/S1470-2045(11)70242-X.
Morrison, V. A. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am. Soc. Hematol. Educ Program 2007, 332–338 (2007).
Diehl, L. F., Karnell, L. H. & Menck, H. R. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on age, gender, treatment, and outcomes of patients with chronic lymphocytic leukemia. Cancer 86, 2684–2692 (1999).
Byrd, J. C. et al. Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase Ib/II study [abstract]. J. Clin. Oncol. 29 (Suppl. 15), 6508 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Woyach, J., Byrd, J. New FluCam combination therapy has familiar limitations. Nat Rev Clin Oncol 9, 14–15 (2012). https://doi.org/10.1038/nrclinonc.2011.191
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.191
